These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16137634)

  • 1. Cell-penetrating peptides: a comparative membrane toxicity study.
    Saar K; Lindgren M; Hansen M; Eiríksdóttir E; Jiang Y; Rosenthal-Aizman K; Sassian M; Langel U
    Anal Biochem; 2005 Oct; 345(1):55-65. PubMed ID: 16137634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of in vitro toxicity of five cell-penetrating peptides by metabolic profiling.
    Kilk K; Mahlapuu R; Soomets U; Langel U
    Toxicology; 2009 Nov; 265(3):87-95. PubMed ID: 19799958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cell penetrating peptides pVEC and W2-pVEC induce transformation of gel phase domains in phospholipid bilayers without affecting their integrity.
    Herbig ME; Assi F; Textor M; Merkle HP
    Biochemistry; 2006 Mar; 45(11):3598-609. PubMed ID: 16533042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct uptake routes of cell-penetrating peptide conjugates.
    Lundin P; Johansson H; Guterstam P; Holm T; Hansen M; Langel U; EL Andaloussi S
    Bioconjug Chem; 2008 Dec; 19(12):2535-42. PubMed ID: 19012426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-penetrating peptides: mechanism and kinetics of cargo delivery.
    Zorko M; Langel U
    Adv Drug Deliv Rev; 2005 Feb; 57(4):529-45. PubMed ID: 15722162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of cell-penetrating peptides (CPPs) as vehicles for intracellular delivery of antisense peptide nucleic acid (PNA).
    Bendifallah N; Rasmussen FW; Zachar V; Ebbesen P; Nielsen PE; Koppelhus U
    Bioconjug Chem; 2006; 17(3):750-8. PubMed ID: 16704214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231.
    Aroui S; Brahim S; De Waard M; Bréard J; Kenani A
    Cancer Lett; 2009 Nov; 285(1):28-38. PubMed ID: 19523755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Pro --> peptoid residue substitution on cell selectivity and mechanism of antibacterial action of tritrpticin-amide antimicrobial peptide.
    Zhu WL; Lan H; Park Y; Yang ST; Kim JI; Park IS; You HJ; Lee JS; Park YS; Kim Y; Hahm KS; Shin SY
    Biochemistry; 2006 Oct; 45(43):13007-17. PubMed ID: 17059217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro uptake and stability study of pVEC and its all-D analog.
    Elmquist A; Langel U
    Biol Chem; 2003 Mar; 384(3):387-93. PubMed ID: 12715889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of simvastatin on erythrocyte membrane fluidity during oxidative stress induced by cardiopulmonary bypass: a randomized controlled study.
    Coccia R; Spadaccio C; Foppoli C; Perluigi M; Covino E; Lusini M; Chello M
    Clin Ther; 2007 Aug; 29(8):1706-17. PubMed ID: 17919551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity methods for CPPs.
    Lundin P; Andaloussi SE; Langel U
    Methods Mol Biol; 2011; 683():195-205. PubMed ID: 21053131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-penetrating peptides for drug delivery across membrane barriers.
    Foged C; Nielsen HM
    Expert Opin Drug Deliv; 2008 Jan; 5(1):105-17. PubMed ID: 18095931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitatively determined uptake of cell-penetrating peptides in non-mammalian cells with an evaluation of degradation and antimicrobial effects.
    Palm C; Netzereab S; Hällbrink M
    Peptides; 2006 Jul; 27(7):1710-6. PubMed ID: 16500001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of a tumor-homing cell-penetrating peptide.
    Myrberg H; Zhang L; Mäe M; Langel U
    Bioconjug Chem; 2008 Jan; 19(1):70-5. PubMed ID: 18001077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of uptake of cell penetrating peptides and their cargoes in permeabilized wheat immature embryos.
    Chugh A; Eudes F
    FEBS J; 2008 May; 275(10):2403-14. PubMed ID: 18397318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein delivery by the cell-penetrating peptide YTA2.
    Myrberg H; Lindgren M; Langel U
    Bioconjug Chem; 2007; 18(1):170-4. PubMed ID: 17226970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemolytic and cytotoxic action of latarcin Ltc2a.
    Vorontsova OV; Egorova NS; Arseniev AS; Feofanov AV
    Biochimie; 2011 Feb; 93(2):227-41. PubMed ID: 20887768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of growth and cancer-induced angiogenesis of aggressive human breast cancer cells (MDA-MB-231) on the chorioallantoic membrane of developing chicken embryos by E-peptide of pro-IGF-I.
    Chen MJ; Chiou PP; Lin P; Lin CM; Siri S; Peck K; Chen TT
    J Cell Biochem; 2007 Aug; 101(5):1316-27. PubMed ID: 17286280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonhemolytic Cell-Penetrating Peptides: Site Specific Introduction of Glutamine and Lysine Residues into the α-Helical Peptide Causes Deletion of Its Direct Membrane Disrupting Ability but Retention of Its Cell Penetrating Ability.
    Kim S; Hyun S; Lee Y; Lee Y; Yu J
    Biomacromolecules; 2016 Sep; 17(9):3007-15. PubMed ID: 27442521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides.
    Nekhotiaeva N; Elmquist A; Rajarao GK; Hällbrink M; Langel U; Good L
    FASEB J; 2004 Feb; 18(2):394-6. PubMed ID: 14656995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.